Orphan drugs und seltene EpilepsienOrphan drugs and rare diseases

被引：0
|
作者：
Andreas Schulze-Bonhage
Ulrich Stephani
机构：
[1] Zentrum für seltene und komplexe Epilepsien in Baden-Württemberg,Epilepsiezentrum/Abt. Prächirurgische Epilepsiediagnostik
[2] Universitätsklinikum Freiburg,European Reference Center ERN EpiCare, Neurozentrum
[3] Universitätsklinikum Schleswig Holstein,Klinik für Kinder
[4] Campus Kiel, und Jugendmedizin II (Neuropädiatrie und Sozialpädiatrie)
[5] DRK,Norddeutsches Epilepsiezentrum für Kinder und Jugendliche
来源：
Zeitschrift für Epileptologie | 2019年 / 32卷 / 4期
关键词：
D O I：
10.1007/s10309-019-00288-6
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：263 / 263
相关论文
共 50 条
  • [41] CRITERIA TO DEFINE RARE DISEASES AND ORPHAN DRUGS: SYSTEMATIC LITERATURE REVIEW
    Abozaid, G.
    Kerr, K.
    McKnight, A.
    Al-Omar, H.
    VALUE IN HEALTH, 2022, 25 (12) : S264 - S264
  • [42] Balancing economic, ethical and equity concerns in orphan drugs and rare diseases
    McCabe, Christopher
    EJHP PRACTICE, 2010, 16 (04): : 22 - 25
  • [43] ORPHAN DRUGS TO TREATING RARE DISEASES: THE ITALIAN WAY FOR AN EARLY ACCESS
    Prada, M.
    Sansone, C.
    Bisagni, D.
    Mantovani, M.
    VALUE IN HEALTH, 2017, 20 (05) : A233 - A234
  • [44] EVOLUTION OF THE UTILIZATION OF THE AIFA 5% FUND FOR ORPHAN DRUGS AND RARE DISEASES
    Tartarelli, F.
    Viola, V.
    Lidonnici, D.
    Marcellusi, A.
    VALUE IN HEALTH, 2023, 26 (12) : S259 - S259
  • [45] Criteria to define rare diseases and orphan drugs: a systematic review protocol
    Abozaid, Ghada Mohammed
    Kerr, Katie
    McKnight, Amy
    Al-Omar, Hussain A.
    BMJ OPEN, 2022, 12 (07):
  • [46] VALUE ASSESSMENT OF ORPHAN DRUGS FOR TREATMENT OF RARE DISEASES: A SYSTEMATIC REVIEW
    Lockhart, C. M.
    Hansen, R. N.
    VALUE IN HEALTH, 2016, 19 (03) : A79 - A79
  • [47] Ultra orphan drugs: the NHS model for managing extremely rare diseases
    Jessop, Edmund
    Upadhyaya, Sheela
    EXPERT OPINION ON ORPHAN DRUGS, 2014, 2 (12): : 1301 - 1308
  • [48] Big Pharma's new model in orphan drugs and rare diseases
    Phillips, M. Ian
    EXPERT OPINION ON ORPHAN DRUGS, 2013, 1 (01): : 1 - 3
  • [49] Ethical Questions Linked to Rare Diseases and Orphan Drugs - A Systematic Review
    Kacetl, Jaroslav
    Maresova, Petra
    Maskuriy, Raihan
    Selamat, Ali
    RISK MANAGEMENT AND HEALTHCARE POLICY, 2020, 13 : 2125 - 2148
  • [50] Orphan drugs and rare diseases: a scientometric review (2000-2014)
    Chen, Chaomei
    Dubin, Rachael
    Kim, Meen Chul
    EXPERT OPINION ON ORPHAN DRUGS, 2014, 2 (07): : 709 - 724
12345